Compounds > naltrexone

naltrexone and Cancer of Ovary

naltrexone has been researched along with Cancer of Ovary in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Donahue, R; McLaughlin, PJ; Zagon, IS1
Donahue, RN; McLaughlin, PJ; Zagon, IS4

Other Studies

6 other study(ies) available for naltrexone and Cancer of Ovary

ArticleYear
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Experimental biology and medicine (Maywood, N.J.), 2013, Volume: 238, Issue:5

    Topics: Apoptosis; Cell Cycle; Female; Gene Expression Regulation, Neoplastic; Humans; Naltrexone; Narcotic Antagonists; Necrosis; Neoplasm Proteins; Opioid Peptides; Ovarian Neoplasms; Receptors, Opioid; Up-Regulation

2013
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:6

    Topics: Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; DNA Replication; Down-Regulation; Enkephalin, Methionine; Female; Humans; Naltrexone; Narcotic Antagonists; Ovarian Neoplasms; Receptors, Opioid; RNA Interference; RNA, Small Interfering; Signal Transduction; Time Factors

2009
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Gynecologic oncology, 2011, Volume: 122, Issue:2

    Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; DNA; Enkephalin, Methionine; Female; Humans; Mice; Mice, Nude; Naltrexone; Narcotic Antagonists; Neovascularization, Pathologic; Ovarian Neoplasms; Receptors, Opioid; Xenograft Model Antitumor Assays

2011
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Experimental biology and medicine (Maywood, N.J.), 2011, Volume: 236, Issue:7

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Naltrexone; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2011
Low-dose naltrexone: harnessing the body's own chemistry to treat human ovarian cancer.
    Experimental biology and medicine (Maywood, N.J.), 2011, Volume: 236, Issue:7

    Topics: Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Naltrexone; Ovarian Neoplasms; Treatment Outcome

2011
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
    Experimental biology and medicine (Maywood, N.J.), 2012, Volume: 237, Issue:2

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enkephalins; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Mice; Mice, Nude; Naltrexone; Neoplasm Transplantation; Ovarian Neoplasms; Receptors, Opioid; Time Factors

2012